Windtree Therapeutics Inc expected to post a loss of 30  cents a share - Earnings Preview

Windtree Therapeutics

25/03/2022 22:58

* Windtree Therapeutics Inc  WINT.OQ   WINT.O  is expected
to show
no change in quarterly revenue when it reports  results on March
28 (estimated). 
    * ​Refinitiv's mean analyst estimate for Windtree
Therapeutics Inc
is for a loss of 30 cents per share. For the same quarter last
year, the company reported a loss of 43 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Windtree
Therapeutics Inc is $8.25​, above​ its last closing price
of $1.04. ​​​

This summary was machine generated March 25 at 22:58 GMT.  All
figures in US dollars  unless otherwise stated